Combination therapy with ropivacaine-loaded liposomes and nutrient deprivation for simultaneous cancer therapy and cancer pain relief

Autophagy allows cancer cells to respond changes in nutrient status by degrading and recycling non-essential intracellular contents.Inhibition of autophagy combined with nutrient deprivation is an effective strategy to treat cancer.Pain is a primary determinant of poor quality of life in advanced cancer patients, but there is currently no satisfactory treatment.In addition, effective treatment of cancer does not efficiently relieve cancer pain, but may increase pain in many cases.Hence, few studies focus on simultaneous cancer therapy and pain relief, and made this situation even worse.Method: Ropivacaine was loaded into tumor-active targeted liposomes.The cytotoxicity of ropivacaine-based combination therapy in B16 and HeLa cells were tested.Moreover, a mice model of cancer pain which was induced by inoculation of melanoma near the sciatic nerve was constructed to assess the cancer suppression and pain relief effects of ropivacaine-based combination therapy.Results: Ropivacaine and ropivacaine-loaded liposomes (Rop-DPRL) were novelly found to damage autophagic degradation.Replicated administration of Rop-DPRL and calorie restriction (CR) could efficiently repress the development of tumor.In addition, administration of Rop-DPRL could relieve cancer pain with its own analgestic ability in a short duration, while repeated administration of Rop-DPRL and CR resulted in continuous alleviation of cancer pain through reduction of VEGF-A levels in advanced cancer mice.Further, dual inhibition of phosphorylation of STAT3 at Tyr705 and Ser727 by Rop-DPRL and CR contribute to the reduction of VEGF-A.Conclusion: Combination therapy with Rop-DPRL and nutrient deprivation simultaneously suppresses cancer growth and relieves cancer pain.